SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4QJ'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EI6_D_PPFD412_1 (PHOSPHONOACETATE HYDROLASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	4 / 8	THR A 334 ASP A 264 HIS A 223 HIS A 227	MG A 602 ( 4.9A) MG A 602 ( 2.6A) 4QJ A 603 ( 4.9A) ZN A 601 (-3.4A)	1.02A	1ei6D-5b25A: undetectable	1ei6D-5b25A: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDU_A_CIAA1003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 11	TYR A 222 PHE A 392 LEU A 409 GLN A 421 PHE A 424	None GOL A 607 (-3.9A) GOL A 607 (-4.6A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	1.05A	1uduA-5b25A: 33.8	1uduA-5b25A: 28.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UDU_B_CIAB2003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 12	TYR A 222 PHE A 392 LEU A 409 GLN A 421 PHE A 424	None GOL A 607 (-3.9A) GOL A 607 (-4.6A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	1.01A	1uduB-5b25A: 33.9	1uduB-5b25A: 28.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 10	TYR A 222 HIS A 223 PHE A 392 GLN A 421 GLY A 423 PHE A 424	None 4QJ A 603 ( 4.9A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-4.2A) 4QJ A 603 (-3.5A)	0.65A	1uhoA-5b25A: 34.9	1uhoA-5b25A: 28.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 10	TYR A 222 LEU A 409 GLN A 421 GLY A 423 PHE A 424	None GOL A 607 (-4.6A) 4QJ A 603 (-3.0A) 4QJ A 603 (-4.2A) 4QJ A 603 (-3.5A)	0.91A	1uhoA-5b25A: 34.9	1uhoA-5b25A: 28.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 HIS A 267 MET A 336 THR A 385 SER A 420 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) None 4QJ A 603 ( 3.9A) None 4QJ A 603 (-4.7A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.67A	1xlxA-5b25A: 44.0	1xlxA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 HIS A 267 MET A 336 THR A 385 PHE A 392 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) None 4QJ A 603 ( 3.9A) None GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.63A	1xlxB-5b25A: 44.0	1xlxB-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 ASP A 370 PRO A 374 TRP A 384 PHE A 392 SER A 420 PHE A 424	None 4QJ A 603 ( 4.9A) ZN A 601 (-2.5A) None None GOL A 607 (-3.9A) 4QJ A 603 (-4.7A) 4QJ A 603 (-3.5A)	0.59A	1xmuA-5b25A: 43.7	1xmuA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PRO A 374 TRP A 384 PHE A 392 SER A 420	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) None None GOL A 607 (-3.9A) 4QJ A 603 (-4.7A)	0.52A	1xmuB-5b25A: 43.9	1xmuB-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PHE A 392 SER A 420 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) GOL A 607 (-3.9A) 4QJ A 603 (-4.7A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.56A	1xomA-5b25A: 44.0	1xomA-5b25A: 38.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 THR A 385 PHE A 392 SER A 420 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) None GOL A 607 (-3.9A) 4QJ A 603 (-4.7A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.62A	1xomB-5b25A: 44.0	1xomB-5b25A: 38.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PRO A 374 THR A 385 SER A 420 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) None None 4QJ A 603 (-4.7A) 4QJ A 603 (-3.5A)	0.44A	1xoqA-5b25A: 44.0	1xoqA-5b25A: 38.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 ASP A 370 PRO A 374 TRP A 384 THR A 385 SER A 420 PHE A 424	None 4QJ A 603 ( 4.9A) ZN A 601 (-2.5A) None None None 4QJ A 603 (-4.7A) 4QJ A 603 (-3.5A)	0.47A	1xoqB-5b25A: 44.0	1xoqB-5b25A: 38.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PHE A 392 GLN A 421 PHE A 424 ILE A 428	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A) None	0.66A	1xosA-5b25A: 43.9	1xosA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PHE A 392 SER A 407	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) GOL A 607 (-3.9A) GOL A 607 (-4.1A)	1.12A	1xosA-5b25A: 43.9	1xosA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	7 / 12	TYR A 222 HIS A 223 MET A 336 SER A 407 GLN A 421 PHE A 424 ILE A 428	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) GOL A 607 (-4.1A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A) None	0.92A	1xotA-5b25A: 44.0	1xotA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	7 / 12	TYR A 222 HIS A 223 MET A 336 SER A 407 SER A 420 PHE A 424 ILE A 428	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) GOL A 607 (-4.1A) 4QJ A 603 (-4.7A) 4QJ A 603 (-3.5A) None	1.08A	1xotA-5b25A: 44.0	1xotA-5b25A: 35.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 12	TYR A 222 HIS A 223 MET A 336 SER A 407 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) GOL A 607 (-4.1A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.81A	1xotB-5b25A: 43.9	1xotB-5b25A: 35.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 11	TYR A 222 HIS A 223 PHE A 392 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.63A	2h42A-5b25A: 34.6	2h42A-5b25A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 12	TYR A 222 HIS A 223 GLU A 391 PHE A 392 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) None GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.84A	2weyA-5b25A: 37.0	2weyA-5b25A: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 12	TYR A 222 HIS A 223 PHE A 392 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.57A	3b2rA-5b25A: 30.3	3b2rA-5b25A: 28.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 PRO A 374 TRP A 384 THR A 385 SER A 420 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) None None None 4QJ A 603 (-4.7A) 4QJ A 603 (-3.5A)	0.43A	3g4lA-5b25A: 43.8	3g4lA-5b25A: 37.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	8 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PRO A 374 TRP A 384 THR A 385 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) None None None 4QJ A 603 (-3.5A)	0.48A	3g4lB-5b25A: 43.6	3g4lB-5b25A: 37.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	7 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PRO A 374 TRP A 384 THR A 385	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) None None None	0.50A	3g4lC-5b25A: 43.5	3g4lC-5b25A: 37.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	3 / 3	SER A 420 GLN A 421 PHE A 424	4QJ A 603 (-4.7A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.54A	3g4lC-5b25A: 43.5	3g4lC-5b25A: 37.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	9 / 12	TYR A 222 HIS A 223 MET A 336 ASP A 370 PRO A 374 TRP A 384 THR A 385 SER A 420 GLN A 421	None 4QJ A 603 ( 4.9A) 4QJ A 603 ( 3.9A) ZN A 601 (-2.5A) None None None 4QJ A 603 (-4.7A) 4QJ A 603 (-3.0A)	0.58A	3g4lD-5b25A: 43.5	3g4lD-5b25A: 37.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	6 / 9	TYR A 222 MET A 336 PHE A 392 GLN A 421 PHE A 424 ILE A 428	None 4QJ A 603 ( 3.9A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A) None	0.75A	3iakA-5b25A: 43.5	3iakA-5b25A: 38.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	4 / 7	TYR A 222 HIS A 223 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.57A	3jwqC-5b25A: 37.7	3jwqC-5b25A: 27.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 11	TYR A 222 HIS A 223 PHE A 392 GLN A 421 PHE A 424	None 4QJ A 603 ( 4.9A) GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.66A	3jwqA-5b25A: 37.8 3jwqD-5b25A: 37.5	3jwqA-5b25A: 27.93 3jwqD-5b25A: 27.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	5 / 9	TYR A 222 PRO A 374 THR A 385 GLN A 421 PHE A 424	None None None 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.47A	3tvxA-5b25A: 43.5	3tvxA-5b25A: 37.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	4 / 7	TYR A 222 PHE A 392 GLN A 421 PHE A 424	None GOL A 607 (-3.9A) 4QJ A 603 (-3.0A) 4QJ A 603 (-3.5A)	0.44A	3tvxB-5b25A: 43.4	3tvxB-5b25A: 37.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A4I_A_TRPA403_0 (TRYPTOPHAN 2,3-DIOXYGENASE)	5b25	CALCIUM/CALMODULIN-D EPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B (Homo sapiens)	4 / 8	ARG A 482 THR A 432 PRO A 431 ILE A 371	None None None 4QJ A 603 (-4.4A)	1.11A	6a4iA-5b25A: undetectable	6a4iA-5b25A: 20.53

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1EI6_D_PPFD412_1","PHOSPHONOACETATE HYDROLASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",4,"THR A 334;ASP A 264;HIS A 223;HIS A 227"," MG A 602 ( 4.9A); MG A 602 ( 2.6A);4QJ A 603 ( 4.9A); ZN A 601 (-3.4A)","1.02A","1ei6D-5b25A:undetectable",null],["1UDU_A_CIAA1003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;PHE A 392;LEU A 409;GLN A 421;PHE A 424","None;GOL A 607 (-3.9A);GOL A 607 (-4.6A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","1.05A","1uduA-5b25A:33.8","1ei6D-5b25A:23.81"],["1UDU_B_CIAB2003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;PHE A 392;LEU A 409;GLN A 421;PHE A 424","None;GOL A 607 (-3.9A);GOL A 607 (-4.6A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","1.01A","1uduB-5b25A:33.9","1uduA-5b25A:28.69"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",6,"TYR A 222;HIS A 223;PHE A 392;GLN A 421;GLY A 423;PHE A 424","None;4QJ A 603 ( 4.9A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-4.2A);4QJ A 603 (-3.5A)","0.65A","1uhoA-5b25A:34.9","1uduB-5b25A:28.69"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;LEU A 409;GLN A 421;GLY A 423;PHE A 424","None;GOL A 607 (-4.6A);4QJ A 603 (-3.0A);4QJ A 603 (-4.2A);4QJ A 603 (-3.5A)","0.91A","1uhoA-5b25A:34.9","1uhoA-5b25A:28.69"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;HIS A 267;MET A 336;THR A 385;SER A 420;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);None;4QJ A 603 ( 3.9A);None;4QJ A 603 (-4.7A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.67A","1xlxA-5b25A:44.0","1uhoA-5b25A:28.69"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;HIS A 267;MET A 336;THR A 385;PHE A 392;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);None;4QJ A 603 ( 3.9A);None;GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.63A","1xlxB-5b25A:44.0","1xlxA-5b25A:35.63"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;ASP A 370;PRO A 374;TRP A 384;PHE A 392;SER A 420;PHE A 424","None;4QJ A 603 ( 4.9A); ZN A 601 (-2.5A);None;None;GOL A 607 (-3.9A);4QJ A 603 (-4.7A);4QJ A 603 (-3.5A)","0.59A","1xmuA-5b25A:43.7","1xlxB-5b25A:35.63"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PRO A 374;TRP A 384;PHE A 392;SER A 420","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);None;None;GOL A 607 (-3.9A);4QJ A 603 (-4.7A)","0.52A","1xmuB-5b25A:43.9","1xmuA-5b25A:35.63"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PHE A 392;SER A 420;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);GOL A 607 (-3.9A);4QJ A 603 (-4.7A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.56A","1xomA-5b25A:44.0","1xmuB-5b25A:35.63"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;THR A 385;PHE A 392;SER A 420;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A);None;GOL A 607 (-3.9A);4QJ A 603 (-4.7A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.62A","1xomB-5b25A:44.0","1xomA-5b25A:38.27"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PRO A 374;THR A 385;SER A 420;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);None;None;4QJ A 603 (-4.7A);4QJ A 603 (-3.5A)","0.44A","1xoqA-5b25A:44.0","1xomB-5b25A:38.27"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;ASP A 370;PRO A 374;TRP A 384;THR A 385;SER A 420;PHE A 424","None;4QJ A 603 ( 4.9A); ZN A 601 (-2.5A);None;None;None;4QJ A 603 (-4.7A);4QJ A 603 (-3.5A)","0.47A","1xoqB-5b25A:44.0","1xoqA-5b25A:38.27"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PHE A 392;GLN A 421;PHE A 424;ILE A 428","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A);None","0.66A","1xosA-5b25A:43.9","1xoqB-5b25A:38.27"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",6,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PHE A 392;SER A 407","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);GOL A 607 (-3.9A);GOL A 607 (-4.1A)","1.12A","1xosA-5b25A:43.9","1xosA-5b25A:35.63"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",7,"TYR A 222;HIS A 223;MET A 336;SER A 407;GLN A 421;PHE A 424;ILE A 428","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A);GOL A 607 (-4.1A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A);None","0.92A","1xotA-5b25A:44.0","1xosA-5b25A:35.63"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",7,"TYR A 222;HIS A 223;MET A 336;SER A 407;SER A 420;PHE A 424;ILE A 428","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A);GOL A 607 (-4.1A);4QJ A 603 (-4.7A);4QJ A 603 (-3.5A);None","1.08A","1xotA-5b25A:44.0","1xotA-5b25A:35.63"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",6,"TYR A 222;HIS A 223;MET A 336;SER A 407;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A);GOL A 607 (-4.1A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.81A","1xotB-5b25A:43.9","1xotA-5b25A:35.63"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;HIS A 223;PHE A 392;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.63A","2h42A-5b25A:34.6","1xotB-5b25A:35.63"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",6,"TYR A 222;HIS A 223;GLU A 391;PHE A 392;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);None;GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.84A","2weyA-5b25A:37.0","2h42A-5b25A:28.53"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;HIS A 223;PHE A 392;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.57A","3b2rA-5b25A:30.3","2weyA-5b25A:25.73"],["3G4L_A_ROFA901_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;PRO A 374;TRP A 384;THR A 385;SER A 420;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A);None;None;None;4QJ A 603 (-4.7A);4QJ A 603 (-3.5A)","0.43A","3g4lA-5b25A:43.8","3b2rA-5b25A:28.49"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",8,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PRO A 374;TRP A 384;THR A 385;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);None;None;None;4QJ A 603 (-3.5A)","0.48A","3g4lB-5b25A:43.6","3g4lA-5b25A:37.96"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",7,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PRO A 374;TRP A 384;THR A 385","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);None;None;None","0.50A","3g4lC-5b25A:43.5","3g4lB-5b25A:37.96"],["3G4L_C_ROFC903_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",3,"SER A 420;GLN A 421;PHE A 424","4QJ A 603 (-4.7A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.54A","3g4lC-5b25A:43.5","3g4lC-5b25A:37.96"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",9,"TYR A 222;HIS A 223;MET A 336;ASP A 370;PRO A 374;TRP A 384;THR A 385;SER A 420;GLN A 421","None;4QJ A 603 ( 4.9A);4QJ A 603 ( 3.9A); ZN A 601 (-2.5A);None;None;None;4QJ A 603 (-4.7A);4QJ A 603 (-3.0A)","0.58A","3g4lD-5b25A:43.5","3g4lC-5b25A:37.96"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",6,"TYR A 222;MET A 336;PHE A 392;GLN A 421;PHE A 424;ILE A 428","None;4QJ A 603 ( 3.9A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A);None","0.75A","3iakA-5b25A:43.5","3g4lD-5b25A:37.96"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",4,"TYR A 222;HIS A 223;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.57A","3jwqC-5b25A:37.7","3iakA-5b25A:38.27"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;HIS A 223;PHE A 392;GLN A 421;PHE A 424","None;4QJ A 603 ( 4.9A);GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.66A","3jwqA-5b25A:37.8;3jwqD-5b25A:37.5","3jwqC-5b25A:27.93"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",5,"TYR A 222;PRO A 374;THR A 385;GLN A 421;PHE A 424","None;None;None;4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.47A","3tvxA-5b25A:43.5","3jwqA-5b25A:27.93;3jwqD-5b25A:27.93"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",4,"TYR A 222;PHE A 392;GLN A 421;PHE A 424","None;GOL A 607 (-3.9A);4QJ A 603 (-3.0A);4QJ A 603 (-3.5A)","0.44A","3tvxB-5b25A:43.4","3tvxA-5b25A:37.67"],["6A4I_A_TRPA403_0","TRYPTOPHAN 2,3-DIOXYGENASE","5b25","CALCIUM\/CALMODULIN-DEPENDENT 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1B","Homo sapiens",4,"ARG A 482;THR A 432;PRO A 431;ILE A 371","None;None;None;4QJ A 603 (-4.4A)","1.11A","6a4iA-5b25A:undetectable","3tvxB-5b25A:37.67"]]